These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 18588357)

  • 1. Aflibercept: AVE 0005, AVE 005, AVE0005, VEGF Trap - Regeneron, VEGF Trap (R1R2), VEGF Trap-Eye.
    Drugs R D; 2008; 9(4):261-9. PubMed ID: 18588357
    [No Abstract]   [Full Text] [Related]  

  • 2. Aflibercept for age-related macular degeneration: a game-changer or quiet addition?
    Browning DJ; Kaiser PK; Rosenfeld PJ; Stewart MW
    Am J Ophthalmol; 2012 Aug; 154(2):222-6. PubMed ID: 22813448
    [TBL] [Abstract][Full Text] [Related]  

  • 3. VEGF Trap-Eye for the treatment of neovascular age-related macular degeneration.
    Dixon JA; Oliver SC; Olson JL; Mandava N
    Expert Opin Investig Drugs; 2009 Oct; 18(10):1573-80. PubMed ID: 19694600
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeted therapy for metastatic colorectal cancer: role of aflibercept.
    Mitchell EP
    Clin Colorectal Cancer; 2013 Jun; 12(2):73-85. PubMed ID: 23102896
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Comparison of the biological principles underlying the action of monoclonal antibody (mAb) and decoy receptor anti-VEGF agents--on the example of ranibizumab (anti-VEGF-A mAb) and aflibercept (decoy VEGFR1-2 receptor)].
    Golik P; ToĊ„ska K
    Klin Oczna; 2012; 114(1):79-83. PubMed ID: 22783753
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antiangiogenic and Antitumor Activities of Aflibercept, a Soluble VEGF Receptor-1 and -2, in a Mouse Model of Hepatocellular Carcinoma.
    Torimura T; Iwamoto H; Nakamura T; Abe M; Ikezono Y; Wada F; Sakaue T; Masuda H; Hashimoto O; Koga H; Ueno T; Yano H
    Neoplasia; 2016 Jul; 18(7):413-24. PubMed ID: 27435924
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aflibercept: an update on recent milestones achieved.
    Palejwala NV; Lauer AK
    Drugs Today (Barc); 2014 Dec; 50(12):779-90. PubMed ID: 25588083
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aflibercept (VEGF Trap-Eye) for the treatment of exudative age-related macular degeneration.
    Stewart MW
    Expert Rev Clin Pharmacol; 2013 Mar; 6(2):103-13. PubMed ID: 23473589
    [TBL] [Abstract][Full Text] [Related]  

  • 9. VEGF-TRAP(R1R2) suppresses choroidal neovascularization and VEGF-induced breakdown of the blood-retinal barrier.
    Saishin Y; Saishin Y; Takahashi K; Lima e Silva R; Hylton D; Rudge JS; Wiegand SJ; Campochiaro PA
    J Cell Physiol; 2003 May; 195(2):241-8. PubMed ID: 12652651
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Angiogenic activity of swine granulosa cells: effects of hypoxia and vascular endothelial growth factor Trap R1R2, a VEGF blocker.
    Bianco F; Basini G; Grasselli F
    Domest Anim Endocrinol; 2005 Apr; 28(3):308-19. PubMed ID: 15760671
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fusion Proteins: Aflibercept (VEGF Trap-Eye).
    Sarwar S; Bakbak B; Sadiq MA; Sepah YJ; Shah SM; Ibrahim M; Do DV; Nguyen QD
    Dev Ophthalmol; 2016; 55():282-94. PubMed ID: 26501481
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aflibercept in epithelial ovarian carcinoma.
    Moroney JW; Sood AK; Coleman RL
    Future Oncol; 2009 Jun; 5(5):591-600. PubMed ID: 19519199
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aflibercept, ipilimumab, and vemurafenib.
    Hussar DA; Au AY
    J Am Pharm Assoc (2003); 2012; 52(2):291-4. PubMed ID: 22370387
    [No Abstract]   [Full Text] [Related]  

  • 14. Clinical applications of VEGF-trap (aflibercept) in cancer treatment.
    Teng LS; Jin KT; He KF; Zhang J; Wang HH; Cao J
    J Chin Med Assoc; 2010 Sep; 73(9):449-56. PubMed ID: 20875616
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intravitreal aflibercept for neovascular age-related macular degeneration.
    Xu D; Kaiser PK
    Immunotherapy; 2013 Feb; 5(2):121-30. PubMed ID: 23413903
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration.
    Heier JS; Brown DM; Chong V; Korobelnik JF; Kaiser PK; Nguyen QD; Kirchhof B; Ho A; Ogura Y; Yancopoulos GD; Stahl N; Vitti R; Berliner AJ; Soo Y; Anderesi M; Groetzbach G; Sommerauer B; Sandbrink R; Simader C; Schmidt-Erfurth U;
    Ophthalmology; 2012 Dec; 119(12):2537-48. PubMed ID: 23084240
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biological, preclinical and clinical characteristics of inhibitors of vascular endothelial growth factors.
    Chong V
    Ophthalmologica; 2012; 227 Suppl 1():2-10. PubMed ID: 22517120
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Single injections of vascular endothelial growth factor trap block ovulation in the macaque and produce a prolonged, dose-related suppression of ovarian function.
    Fraser HM; Wilson H; Rudge JS; Wiegand SJ
    J Clin Endocrinol Metab; 2005 Feb; 90(2):1114-22. PubMed ID: 15562010
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Role of VEGF in diseases of the retina].
    Barquet LA
    Arch Soc Esp Oftalmol; 2015 Mar; 90 Suppl 1():3-5. PubMed ID: 25925044
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.